 |
SV Life Sciences Fund ISVLSF I closed in 1994 with total commitments of $100 million. As at 31 March 2010, SVLSF I had invested $123 million in 31 portfolio companies. To go to individual portfolio companies websites please click on company logo. Biotechnology / Biopharmaceuticals
Allos Therapeutics: US - Exited
First investment: 1998 - Early Stage Allos Therapeutics was developing and commercializing innovative small molecule therapeutics for the treatment of cancer. 
Axys Pharmaceuticals: US - Exited
First investment: 1994 - Early Stage Axys developed a protease-inhibitor based products for cancer & inflammatory diseases. 
Cerebrus: UK - Exited
First investment: 1995 - Start Up Cerebrus CNS drug discovery (Acquired by Nigra, which was then bought by Vernalis) 
Cytomed: US - Exited
First investment: 1997 - Early Stage Cytomed was a leukotriene inhibitors for asthma (Acquired by LeukoSite Inc and then by Millenium). 
Geltex Pharmaceuticals: US - Exited
First investment: 1995 - Early Stage Further investment: 1998 - Expansion Geltex developed novel non-absorbed pharmaceuticals. Geltex was acquired by Genzyme Corporation after our exit. 
Incyte Pharmaceuticals: UK - Exited
First investment: 1996 - Start Up Functional genomics (Acquired by Incyte). 
Kinetix Pharmaceuticals: US - Exited
First investment: 1999 - Start Up Kinase targeted drug discovery (Acquired by Amgen). 
LeukoSite: US - Exited
First investment: 1994 - Start Up LeukoSite was a treatment of Inflammatory diseases and cancer (Acquired by Millenium). 
Metris Therapeutics: UK - Exited
First investment SVLSF I: 1998 - Start Up First investment SVLSF II: 2000 - Start Up Metris is a women’s healthcare company that is developing drugs for the treatment of chronic gynecological and menstrual conditions. 
Micromet: Germany
First investment: 1998 - Start Up Micromet designs and develops novel antibody derived therapeutics for the treatment of cancer diseases. These drugs are unique in their ability to engage immune effector cells to selectively eliminate disease causing cells. 
Shire Pharmaceuticals: US - Exited
First investment: 1994 - Early Stage Shire Pharmaceuticals - osteoporosis and Alzheimer's disease. 
Strides Arcolab: India - Exited
First investment: 1997 - Expansion Strides Arcolab was a manufacturer of generic pharmaceuticals. 
Triangle Pharmaceuticals: US - Exited
First investment: 1995 - Start Up Triangle Pharmaceuticals was an antiviral and anticancer drug development company (Acquired by Gilead). 
Vanguard Medica (Vernalis): UK - Exited
First investment: 1995 - Early Stage Vanguard Medica was an antiviral and anticancer drug development company. (Acquired by Vernalis) 
| |
